Selective inhibition of BET bromodomains
By P. Filippakopoulos, J. Qi, S. Picaud, Yao Shen, William B. Smith, O. Fedorov, Elizabeth M. Morse, T. Keates, T. Hickman, I. Felletár and 15 more. Nature, 2010
4,002 citations recorded by the source corpus.
Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic ‘writers’ and ‘erasers’. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein–protein interactions of epigenetic ‘readers’, and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/b59b7906fa40c38837b1a74a80cc2f0631892394
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
- Richard A. Young
- James E. Bradner
- M. Dawson
- Dean W. Felsher
- Tony Kouzarides
- Scott W. Lowe
- Peter A. Jones
- S. Baylin
In Molecular Biology
Citations in the corpus
- Intrinsically disordered proteins: regulation and disease. (2011, background): “Another study identified a cell-permeable compound that blocks the interaction between the bromodomain protein BRD4 and the disordered histone tail by binding specifically to the groove on the bromodomain [60].”
- Epigenetic Determinants of Cancer. (2016, background): “1 of Qi 2014) (Filippakopoulos et al. 2010; Delmore et al. 2011; Zuber et al. 2011; Dawson and Kouzarides 2012).”
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia (2011, background): “The recent development of small-molecule BET bromodomain inhibitor”
- MYC activation is a hallmark of cancer initiation and maintenance. (2014, background): “However, MYC has yet to be successfully therapeutically targeted for the treatment of cancer, as most transcription factors are generally considered “undruggable” (Verdine and Walensky 2007; Filippakopoulos et al. 2010; Delmore et al. 2011; Yan and Higgins 2013).”
- Cellular Senescence: Aging, Cancer, and Injury. (2019, background): “A promising class of compounds found to suppress MYC transcription, thereby enhancing senescence, are represented by BET protein bromodomain inhibitors such as JQ1 or CPI-0610 and are currently tested in clinical trials in different cancer patients (87, 118).”
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers (2013, background): “Although BRD4 is widely expressed in mouse tissues, mice are reasonably tolerant of the levels of BET bromodomain inhibition that inhibit certain tumors in mouse models (Dawson et al., 2011; Delmore et al., 2011; Filippakopoulos et al., 2010; Mertz et al., 2011; Zuber et al., 2011).”
- Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma (2013, neutral): “(F) GSEA plots of functionally defined MYC and E2F target gene sets in vehicle- vs. JQ1-treated cells at 24 hr. (G) Protein abundance of MYC and E2F in the indicated DLBCL lines treated with vehicle or JQ1S or JQ1R (500 nM) (24 hr).”
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family (2012, background): “…specific Kac competitive inhibitors for BET BRDs provides a compelling case for targeting these BRDs for the treatment of an extremely aggressive subtype of squamous cell carcinoma that is caused by chromosomal rearrangement of BRD3 or BRD4 with NUT (Filippakopoulos et al., 2010; French, 2010b).”
- An Oncogenic Super-Enhancer Formed Through Somatic Mutation of a Noncoding Intergenic Element (2014, background): “Drugs that target key components of the transcriptional machinery, such as BRD4 and CDK7 (12, 13, 17), have recently been shown to preferentially target tumor-specific super-enhancers, which provides a novel strategy to capitalize on these abnormalities for improved cancer therapy.”